Cabergoline and Weed
Edited by Hugh Soames
Advertising: We may earn a commission if you buy anything via our advertising or external links
Cabergoline and Weed
Most people who consume marijuana do so for its mood-altering and relaxing abilities. Weed gives people a high and allows them to relax. However, heavy consumption of weed can cause unwanted results. It can increase the anxiety and depression a person experiences, and it can interact with certain other drugs including Cabergoline. It is important to remember that interactions do occur with all types of drugs, to a great or lesser extent and this article details the interactions of mixing Cabergoline and Weed.
Mixing Cabergoline and Weed
Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson’s disease, and for other indications. It is taken by mouth.
Cabergoline is an ergot derivative and a potent dopamine D2 receptor agonist.
Cabergoline was patented in 1980 and approved for medical use in 1993. It is on the World Health Organization’s List of Essential Medicines.
Cabergoline is frequently used as a first-line agent in the management of prolactinomas due to its higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is often still chosen since there is less data on safety in pregnancy for cabergoline.
It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs, such as reduced libido and anorgasmia. It also has been suggested that it has a possible recreational use in reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession, and at least two scientific studies support those speculations. Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF). Also, a study on rats found that cabergoline reduces voluntary alcohol consumption, possibly by increasing GDNF expression in the ventral tegmental area. It may be used in the treatment of restless legs syndrome.[citation needed]
Relatively little is known about the effects of this medication during pregnancy and lactation. In some cases the related bromocriptine may be an alternative when pregnancy is expected.
Side effects are mostly dose dependent. Much more severe side effects are reported for treatment of Parkinson’s disease and (off-label treatment) for restless leg syndrome which both typically require very high doses. The side effects are considered mild when used for treatment of hyperprolactinemia and other endocrine disorders or gynecologic indications where the typical dose is one hundredth to one tenth that for Parkinson’s disease.
Cabergoline requires slow dose titration (2–4 weeks for hyperprolactinemia, often much longer for other conditions) to minimize side effects. The extremely long bioavailability of the medication may complicate dosing regimens during titration and require particular precautions.
Cabergoline is considered the best tolerable option for hyperprolactinemia treatment although the newer and less tested quinagolide may offer similarly favourable side effect profile with quicker titration times.
Approximately 200 patients with newly diagnosed Parkinson’s disease participated in a clinical study of cabergoline monotherapy. Seventy-six (76) percent reported at least one side effect. These side effects were chiefly mild or moderate:
In a combination study with 2,000 patients also treated with levodopa, the incidence and severity of side effects was comparable to monotherapy. Encountered side effects required a termination of cabergoline treatment in 15% of patients. Additional side effects were infrequent cases of hematological side effects, and an occasional increase in liver enzymes or serum creatinine without signs or symptoms.
As with other ergot derivatives, pleuritis, exudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. These side effects are noted in less than 2% of patients. They require immediate termination of treatment. Clinical improvement and normalization of X-ray findings are normally seen soon after cabergoline withdrawal. It appears that the dose typically used for treatment of hyperprolactinemia is too low to cause this type of side effects.
In two studies published in the New England Journal of Medicine on January 4, 2007, cabergoline was implicated along with pergolide in causing valvular heart disease. As a result of this, the FDA removed pergolide from the U.S. market on March 29, 2007. Since cabergoline is not approved in the U.S. for Parkinson’s Disease, but for hyperprolactinemia, the drug remains on the market. The lower doses required for treatment of hyperprolactinemia have been found to be not associated with clinically significant valvular heart disease or cardiac valve regurgitation.
No interactions were noted with levodopa or selegiline. The drug should not be combined with other ergot derivatives. Dopamine antagonists such as antipsychotics and metoclopramide counteract some effects of cabergoline. The use of antihypertensive drugs should be intensively monitored because excessive hypotension may result from the combination.
Cabergoline is a long-acting dopamine D2 receptor agonist. In-vitro rat studies show a direct inhibitory effect of cabergoline on the prolactin secretion in the lactotroph cells of the pituitary gland and cabergoline decreases serum prolactin levels in reserpinized rats. Although cabergoline is commonly described principally as a D2 receptor agonist, it also possesses significant affinity for the dopamine D3, and D4, serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C, and α2-adrenergic receptors, as well as moderate/low affinity for the dopamine D1, serotonin 5-HT7, and α1-adrenergic receptors. Cabergoline functions as an partial or full agonist at all of these receptors except for the 5-HT7, α1-adrenergic, and α2-adrenergic receptors, where it acts as an antagonist. Cabergoline has been associated with cardiac valvulopathy due to activation of 5-HT2B receptors.
Following a single oral dose, resorption of cabergoline from the gastrointestinal (GI) tract is highly variable, typically occurring within 0.5 to 4 hours. Ingestion with food does not alter its absorption rate. Human bioavailability has not been determined since the drug is intended for oral use only. In mice and rats the absolute bioavailability has been determined to be 30 and 63 percent, respectively. Cabergoline is rapidly and extensively metabolized in the liver and excreted in bile and to a lesser extent in urine. All metabolites are less active than the parental drug or inactive altogether. The human elimination half-life is estimated to be 63 to 68 hours in patients with Parkinson’s disease and 79 to 115 hours in patients with pituitary tumors. Average elimination half-life is 80 hours.
Cabergoline was first synthesized by scientists working for the Italian drug company Farmitalia-Carlo Erba in Milan who were experimenting with semisynthetic derivatives of the ergot alkaloids, and a patent application was filed in 1980. The first publication was a scientific abstract at the Society for Neuroscience meeting in 1991.
Farmitalia-Carlo Erba was acquired by Pharmacia in 1993, which in turn was acquired by Pfizer in 2003.
Cabergoline was first marketed in The Netherlands as Dostinex in 1992. The drug was approved by the FDA on December 23, 1996. It went generic in late 2005 following US patent expiration.
Brand names of cabergoline include Cabaser, Dostinex, Galastop (veterinary), and Kelactin (veterinary), among others.
Cabergoline was studied in one person with Cushing’s disease, to lower adrenocorticotropic hormone (ACTH) levels and cause regression of ACTH-producing pituitary adenomas.
Research has found that anxiety is one of the leading symptoms created by marijuana in users, and that there is a correlation between Cabergoline and Weed and an increase in anxiety.
Anyone mixing Cabergoline and weed is likely to experience side effects. This happens with all medications whether weed or Cabergoline is mixed with them. Side effects can be harmful when mixing Cabergoline and weed. Doctors are likely to refuse a patient a Cabergoline prescription if the individual is a weed smoker or user. Of course, this could be due to the lack of studies and research completed on the mixing of Cabergoline and Weed.
Heavy, long-term weed use is harmful for people. It alters the brain’s functions and structure, and all pharmaceuticals and drugs including Cabergoline are designed to have an impact on the brain. There is a misplaced belief that pharmaceuticals and medication work by treating only the parts of the body affected yet this is obviously not the case in terms of Cabergoline. For example, simple painkiller medication does not heal the injury, it simply interrupts the brains functions to receive the pain cause by the injury. To say then that two drugs, Cabergoline and Weed, dol not interact is wrong. There will always be an interaction between Cabergoline and Weed in the brain11.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/.
One of the milder side effects of mixing Cabergoline and Weed is Scromiting. This condition, reportedly caused by mixing Cabergoline and Weed, describes a marijuana-induced condition where the user experiences episodes of violent vomiting, which are often so severe and painful that they cause the person to scream. The medical term for Scromiting by mixing Cabergoline and Weed is cannabinoid hyperemesis syndrome, or CHS. For these reasons, some people choose to quit smoking weed.
It was first included in scientific reports in 2004. Since then, researchers have determined that Scromiting is the result of ongoing, long-term use of marijuana—particularly when the drug contains high levels of THC, marijuana’s main psychoactive ingredient. Some experts believe that the receptors in the gut become overstimulated by THC, thus causing the repeated cycles of vomiting.
In the long run, a person can become even more depressed. There is a belief that marijuana is all-natural and not harmful to a person’s health. This is not true and Cabergoline and weed can cause health issues the more a person consumes it.
How does Weed effect the potency of Cabergoline?
The way in which the body absorbs and process Cabergoline may be affected by weed. Therefore, the potency of the Cabergoline may be less effective. Marijuana inhibits the metabolization of Cabergoline. Not having the right potency of Cabergoline means a person may either have a delay in the relief of their underlying symptoms.
A person seeking Cabergoline medication that uses weed should speak to their doctor. It is important the doctor knows about a patient’s weed use, so they can prescribe the right Cabergoline medication and strength. Or depending on level of interactions they may opt to prescribe a totally different medication. It is important for the doctor to know about their patient’s marijuana use. Weed is being legalized around the US, so doctors should be open to speaking about a patient’s use of it.
Sideffects of Cabergoline and Weed
Many individuals may not realize that there are side effects and consequences to mixing Cabergoline and Weed such as:
- Dizziness
- Sluggishness
- Drowsiness
- Shortness of breath
- Itching
- Hives
- Palpitations
- Respiratory Depression
- Cardiac Arrest
- Coma
- Seizures
- Death
Interestingly, it is impossible to tell what effect mixing this substance with Weed will have on an individual due to their own unique genetic make up and tolerance. It is never advisable to mix Cabergoline and Weed due to the chances of mild, moderate and severe side effects. If you are having an adverse reaction from mixing Cabergoline and Weed it’s imperative that you head to your local emergency room. Even mixing a small amount of Cabergoline and Weed is not recommended.
Taking Cabergoline and Weed together
People who take Cabergoline and Weed together will experience the effects of both substances. Technically, the specific effects and reactions that occur due to frequent use of Cabergoline and weed depend on whether you consume more weed in relation to Cabergoline or more Cabergoline in relation to weed.
The use of significantly more weed and Cabergoline will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Cabergoline may experience effects such as:
- reduced motor reflexes from Cabergoline and Weed
- dizziness from Weed and Cabergoline
- nausea and vomiting due to Cabergoline and Weed
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Cabergoline leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Mixing weed and Cabergoline
The primary effect of weed is influenced by an increase in the concentration of the inhibitory neurotransmitter GABA, which is found in the spinal cord and brain stem, and by a reduction in its effect on neuronal transmitters. When weed is combined with Cabergoline this primary effect is exaggerated, increasing the strain on the body with unpredictable results.
Weed and Cabergoline affects dopamine levels in the brain, causing the body both mental and physical distress. Larger amounts of Cabergoline and weed have a greater adverse effect yet leading medical recommendation is that smaller does of Cabergoline can be just as harmful and there is no way of knowing exactly how Cabergoline and weed is going to affect an individual before they take it.
Taking Cabergoline and weed together
People who take Cabergoline and weed together will experience the effects of both substances. The use of significantly more Cabergoline with weed will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Cabergoline may experience effects such as:
- reduced motor reflexes from Cabergoline and weed
- dizziness from weed and Cabergoline
- nausea and vomiting of the Cabergoline
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Cabergoline leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Weed Vs Cabergoline
Taking Cabergoline in sufficient quantities increases the risk of a heart failure. Additionally, people under the influence of Cabergoline and weed may have difficulty forming new memories. With weed vs Cabergoline in an individual’s system they become confused and do not understand their environment. Due to the synergistic properties of Cabergoline when mixed with weed it can lead to confusion, anxiety, depression and other mental disorders. Chronic use of Cabergoline and weed can lead to permanent changes in the brain22.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741114/.
Cabergoline Vs Weed
Studies investigating the effects of drugs such as Cabergoline and weed have shown that the potential for parasomnia (performing tasks in sleep) is dramatically increased when Cabergoline and weed are combined. Severe and dangerous side effects can occur when medications are mixed in the system, and sleep disorders are a common side effect of taking weed and Cabergoline together.
When a small to medium amount of weed is combined with Cabergoline, sleep disorders such as sleep apnea can occur. According to the latest data from the US Centers for Disease Control and Prevention (CDC) most ER visits and hospitalizations caused by too much weed were associated with other substances such as Cabergoline.
How long after taking Cabergoline can I smoke weed or take edibles?
To avoid any residual toxicity it is advisable to wait until the Cabergoline has totally cleared your system before taking weed, even in small quantities.
Overdose on Cabergoline and weed
In the case of Overdose on Cabergoline or if you are worried after mixing Cabergoline and weed, call a first responder or proceed to the nearest Emergency Room immediately.
If you are worried about someone who has taken too much Cabergoline or mixed weed with Cabergoline then call a first responder or take them to get immediate medical help. The best place for you or someone you care about in the case of a medical emergency is under medical supervision. Be sure to tell the medical team that there is a mix of Cabergoline and weed in their system.
Excessive Weed intake and result in scromiting, chs, and anxiety disorder. It is advisable to quit vaping weed if you are feeling these symptoms.
Mixing Cabergoline and weed and antidepressants
Weed users feeling depressed and anxious may be prescribed antidepressant medication. There are some antidepressant users who also use Cabergoline and weed. These individuals may not realize that there are side effects and consequences to consuming both Cabergoline, marijuana and a range of antidepressants.
Studies on weed, Cabergoline and antidepressants is almost nil. The reason for so little information on the side effects of the two is mostly down to marijuana being illegal in most places – although a number of states in the United States have legalized the drug.
Self-medicating with Weed and Cabergoline
A lot of people suffer from depression caused by weed and Cabergoline. How many? According to Anxiety and Depression Association of America (ADAA), in any given year, it is estimated that nearly 16 million adults experience depression. Unfortunately, that number is likely to be wrong due to under reporting. Many people do not report suffering from depression because they do not want to be looked at as suffering from a mental illness. The stigmas around mental health continue and people do not want to be labeled as depressed.
Potential side effects from mixing Cabergoline and weed
Quitting weed to take Cabergoline
Medical professionals say an individual prescribed or taking Cabergoline should not stop using weed cold turkey. Withdrawal symptoms can be significant. Heavy pot users should especially avoid going cold turkey. The side effects of withdrawal from weed include anxiety, irritability, loss of sleep, change of appetite, and depression by quitting weed cold turkey and starting to take Cabergoline.
A person beginning to use Cabergoline should cut back on weed slowly. While reducing the amount of weed use, combine it with mindfulness techniques and/or yoga. Experts stress that non-medication can greatly improve a person’s mood.
Weed and Cabergoline can affect a person in various ways. Different types of marijuana produce different side effects. Side effects of weed and Cabergoline may include:
- loss of motor skills
- poor or lack of coordination
- lowered blood pressure
- short-term memory loss
- increased heart rate
- increased blood pressure
- anxiety
- paranoia
- increased energy
- increased motivation
Mixing Cabergoline and weed can also produce hallucinations in users. This makes marijuana a hallucinogenic for some users. Weed creates different side effects in different people, making it a very potent drug. Now, mixing Cabergoline or other mental health drugs with weed can cause even more unwanted side effects.
Mixing drugs and weed conclusion
Long-term weed use can make depression and anxiety worse. In addition, using marijuana can prevent Cabergoline from working to their full potential33.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/. Weed consumption should be reduced gradually to get the most out of prescription medication. Marijuana is a drug and it is harmful to individual’s long-term health. Weed has many side effects and the consequences are different to each person who uses it, especially when mixed with Cabergoline.
If you take Cabergoline, and also drink Alcohol or MDMA, you can research the effects of Cabergoline and Alcohol , Cabergoline and Cocaine as well as Cabergoline and MDMA here.
To find the effects of other drugs and weed refer to our Weed and Other Drugs Index A to L or our Weed and Other Drugs Index M-Z.
Or you could find what you are looking for in our Alcohol and Interactions with Other Drugs index A to L or Alcohol and Interactions with Other Drugs index M to Z , Cocaine and Interactions with Other Drugs index A to L or Cocaine and Interactions with Other Drugs index M to Z or our MDMA and Interactions with Other Drugs Index A to L or MDMA and Interactions with Other Drugs Index M to Z.
Cabergoline and Weed
Counselling for Weed Addiction; Low Cost - Qualified Therapists - Available Now - 20% Off
We may make a commission if you purchase anything via the adverts or links on this page.
Betterhelp is for anyone suffering from mental health issues. Whether you suffer from anxiety, depression, weed addiction, eating disorders, or just need someone to speak to, Betterhelp can pair you with a qualified therapist.
In the wake of the pandemic, an increasing number of people have sought out therapeutic and conseling services to help with weed cessation. Better Help has seen a massive rise in people seeking help over the last two to three years.
If you or someone you care about is smoking or ingesting a level of weed that makes their life become unmanageable, Betterhelp has counselors and therapists on hand to help for less that $90 per week.
Specializations | Burnout, Anxiety, Depression, Stress, Anger Management, Dependencies, Grief, Seasonal Depressive Disorder, Life Crisis, Smoking Cessation, Weed Cessation (among others)
Betterhelp Cost | The standard fee for BetterHelp therapy is only $60 to $90 per week or $240 to $360 per month.
Key Takeaways |
- Largest online therapy platform
- Low cost
- Good for stopping weed
- Messaging
- Live video
- Phone calls
- Live chat
- No lock in contracts
- Cancel anytime
- Licensed and accredited therapists
Discounts Available | We have negotiated a generous 20% discount for readers of our website. Press Here to get 20% Off
